Literature DB >> 11535306

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.

J Schneider1, J A Langermans, S C Gilbert, T J Blanchard, S Twigg, S Naitza, C M Hannan, M Aidoo, A Crisanti, K J Robson, G L Smith, A V Hill, A W Thomas.   

Abstract

Two chimpanzees were vaccinated intramuscularly against malaria using plasmid DNA expressing the pre-erythrocytic antigens thrombospondin related adhesion protein (PfTRAP) and liver stage specific antigen-1 (PfLSA-1) of Plasmodium falciparum together with GM-CSF protein. A recombinant modified vaccinia virus Ankara (MVA) expressing PfTRAP was injected intramuscularly 6 weeks later to boost the immune response. This sequence of antigen delivery induced a specific and long-lasting T cell and antibody response to PfTRAP as detected by ELISPOT assay and ELISA. Antibody responses were detected after four DNA injections, and were boosted by injection of recombinant MVA expressing PfTRAP. Interferon-gamma secreting antigen-specific T cells were detected in both animals, but only after boosting with recombinant MVA. By screening a panel of PfTRAP-derived peptides, an epitope was identified that was recognized by cytotoxic T lymphocytes in one of the chimpanzees studied. T cells specific for this epitope were present in PBMCs and liver-infiltrating lymphocytes at a frequency of between 1 in 200 and 1 in 500. The high immunogenicity of this prime-boost regimen in chimpanzees supports further assessment of this delivery strategy for the induction of protection against P. falciparum malaria in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535306     DOI: 10.1016/s0264-410x(01)00260-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination.

Authors:  Felicia Watson; Melanie Shears; Jokichi Matsubara; Anya Kalata; Annette Seilie; Irene Cruz Talavera; Tayla Olsen; Moriya Tsuji; Sumana Chakravarty; B Kim Lee Sim; Stephen Hoffman; Sean Murphy
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

2.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

3.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289

4.  Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.

Authors:  S Sridhar; A Reyes-Sandoval; S J Draper; A C Moore; S C Gilbert; G P Gao; J M Wilson; A V S Hill
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

5.  A heterologous 'prime-boost' anti-PEDV immunization for pregnant sows protects neonatal piglets through lactogenic immunity against PEDV.

Authors:  Z Wen; Z Xu; Q Zhou; W Li; Y Wu; Y Du; L Chen; C Xue; Y Cao
Journal:  Lett Appl Microbiol       Date:  2019-07-30       Impact factor: 2.858

6.  Vaccines: Underlying Principles of Design and Testing.

Authors:  Sallay Kallon; Shahryar Samir; Nilu Goonetilleke
Journal:  Clin Pharmacol Ther       Date:  2021-03-11       Impact factor: 6.875

7.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

8.  A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

Authors:  Elena López-Gil; Gema Lorenzo; Esther Hevia; Belén Borrego; Martin Eiden; Martin Groschup; Sarah C Gilbert; Alejandro Brun
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11

9.  Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites.

Authors:  M Sedegah; W W Weiss; S L Hoffman
Journal:  Parasite Immunol       Date:  2007-11       Impact factor: 2.280

10.  DNA vaccines: designing strategies against parasitic infections.

Authors:  Catherine Ivory; Kris Chadee
Journal:  Genet Vaccines Ther       Date:  2004-12-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.